Zagazig University Medical Journal
Volume 27
Issue 3 May, 2021

Article 19

April 2021

New Screening non- invasive tool for Nonalcoholic Steatohepatitis
in High-Risk Individuals
Yahya Mohamed Elhamdi
M.B.B.Ch, Faculty of Medicine – Zagazig University, larynyahya@gmail.com

Alaa Ahmed Farag
Assistant Professor of Internal Medicine, Faculty of Medicine, Zagazig University,
alaa.farag@hotmail.com

Ayman Magd Eldin Mohammed Sadek
Lecturer of Internal Medicine, Faculty of Medicine, Zagazig University, ayman.sadek@hotmail.com

Sameh Saber Bayoumi
Assistant Professor of Radiology, Faculty of Medicine, Zagazig University, sameh.bayoumi@gmail.com

Follow this and additional works at: https://digitalcommons.aaru.edu.jo/zumj

Recommended Citation
Elhamdi, Yahya Mohamed; Farag, Alaa Ahmed; Sadek, Ayman Magd Eldin Mohammed; and Bayoumi,
Sameh Saber (2021) "New Screening non- invasive tool for Nonalcoholic Steatohepatitis in High-Risk
Individuals," Zagazig University Medical Journal: Vol. 27 : Iss. 3 , Article 19.
Available at: https://digitalcommons.aaru.edu.jo/zumj/vol27/iss3/19

This Original Article is brought to you for free and open access by Arab Journals Platform. It has been accepted for
inclusion in Zagazig University Medical Journal by an authorized editor. The journal is hosted on Digital Commons,
an Elsevier platform. For more information, please contact rakan@aaru.edu.jo, marah@aaru.edu.jo,
u.murad@aaru.edu.jo.

Elhamdi et al.: New Screening non- invasive tool for Nonalcoholic Steatohepatitis

Manuscript ID
DOI

ZUMJ-2006-1883
10.21608/zumj.2020.33313.1883

ORIGINAL ARTICLE

New Screening Non- Invasive Tool for Nonalcoholic Steatohepatitis in High-Risk
Individuals
Alaa A. Farag (1), Yahya Mohamed Elhamdi (2), Sameh Saber Bayoumi (3), Ayman
M. E. M. Sadek(1)
(1) Internal Medicine Department, Faculty of Medicine - Zagazig University
(2) Internal Medicine Department, Tripoli University – Libya
(3) Radiology Department, Faculty of Medicine - Zagazig University
Corresponding author:
Yahya Mohamed
Elhamdi
M.B.B.Ch, Internal
Medicine Department,
Faculty of Medicine,
Tripoli University Libya
larynyahya@gmail.com
Submit Date

2020-06-24

Revise Date

2021-03-04

Accept Date

2020-11-18

ABSTRACT
Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver
disease which includes simple steatosis and nonalcoholic steatohepatitis
(NASH). The current study aimed to develop a non-invasive tool to predict
NASH in patients with NAFLD. Patients and Methods: A cross-sectional
study was carried on (80) patients presenting to the Hepatology /Internal
Medicine Outpatient Clinic, Zagazig University Hospitals suffering from
dyspeptic symptoms, fatigue and unexplained elevation of aminotransferases
from July 2019 to January 2020. All patients were subjected to liver function
tests, lipid profile, fasting blood sugar, serological markers, abdominal ultrasonographic examination and Fibroscan evaluation. The new model score
included the following clinical and laboratory parameters [body mass index
(BMI), US of liver, Liver stiffness, low-density lipoproteins (LDL), highdensity lipoprotein (HDL), triglyceride (TG), Alanine transferase (ALT),
Aspartame transaminase (AST), AST/ALT ratio, Platelet, mean platelet
volume (MPV), Ferritin and Fasting Blood Glucose] Results: current results
showed a sensitivity of the new score in the detection of NASH (97.9%) versus
91.7% and 89.6% for NAFLD score and BARD score respectively, but
GULAB score was associated with a 100% sensitivity, at a cutoff level of
1.5. The area under the curve for the new score was is 0.789 versus 0.921,
0.925, and 0.996 for NAFLD, BARD, and GULAB scores respectively.
Conclusion: The new model score considered simple, non-invasive and lowcost tool and can be used as a good negative test to exclude NASH in the
screening of high risk patients and markedly reduce the need for liver
biopsies in NAFLD patients.
Keywords: Nonalcoholic steatohepatitis, Steatosis, Fibrosis

INTRODUCTION
on-alcoholic
fatty
liver
disease
(NAFLD) is rapidly becoming one of the
most common causes of chronic liver disease
worldwide and is now a major cause of liverrelated morbidity and mortality [1].
NASH is a pathophysiological stage
activated by the continuous deposition of
excess liver triglycerides (steatosis) due to
increased dietary fat intake or by de novo
lipogenesis. It is also characterized by insulin
resistance (IR), inflammation and oxidative
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stress that eventually lead to fibrosis,
cirrhosis, and in some cases, liver cancer [2].
However, NASH is more progressive
and includes features of steatosis with
hepatocyte injury, lobular inflammation, and
fibrosis. Evidence suggested a possible
increase in the risk of liver cirrhosis and
hepatocellular carcinoma [3].
Conventionally, NASH is a histologic
diagnosis based on liver biopsy (LB) when all
other causes of liver damage have been
discarded in which hepatocyte ballooning,
inflammation, and fibrosis is demonstrated.
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Alternatively, non-invasive strategies that
include liver stiffness measurement (LSM)
using transient elastography (TE) and other
surrogate scores such as European Liver
Fibrosis (ELF), Fibrosis-4 (FIB-4), and Nonalcoholic fatty liver disease Fibrosis Score
(NFS) are used to spare the patient of
histology examination. However, some noninvasive diagnostic tools may be unfeasible
for screening patients at early stages of
disease among the general population who are
overweight and obesity, which may also
hinder the study of the natural history of
NASH [4].
The current study aimed to develop a
non-invasive tool to predict NASH in patients
with NAFLD.
PATIENTS AND METHODS
A cross-sectional study was carried on
(80) Egyptian patients presenting to the
Hepatology Outpatient Clinic, Zagazig
University Hospitals suffering from dyspeptic
symptoms, fatigue and unexplained elevation
of aminotransferases, during the period from
July 2019 to January 2020. Fig. (1), showed
the flow chart of the patients' selection
process.
A written formal consent to participate
in the study was signed by the patients, the
study was approved by the research ethical
committee of Faculty of Medicine, Zagazig
University (ZU-IRB # 4418). The study was
done according to The Code of Ethics of the
World Medical Association (Declaration of
Helsinki) for studies involving humans.
Sample size: assuming that number of
steatohepatic patient is 120 and ppv of
biochemical and imaging is 80% ,sample was
calculated to be 80 cases using EPI info 7
program with test power 80% ,CI 95%
Inclusion criteria: Patients who are
suggested to have fatty liver by ultrasound.
Age: > 18 years. Gender: male or female
Exclusion criteria: Alcoholic fatty liver
disease (alcohol intake exceeding 40 g/d in
males and 20 g/d in females, over the past 5
years). Concomitant chronic hepatitis B and
C. Autoimmune hepatitis or primary biliary
cholangitis. Drug induced hepatitis or toxic
hepatitis. Genetic and metabolic liver
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diseases. Liver and biliary malignancy other
than HCC.
The participants were allocated into two
groups according to presence of NASH as
follow:
1- Group I (48 patients): This group included
patients with risk of NASH.
2- Group II (32 patients): This group included
patients without risk of NASH.
Flow-chart for the screening of NAFLD
The EASL-EASD-EASO Guidelines
recommended to screen the presence of
NAFLD through a first step based on the use
of ultrasound or serum biomarkers to evaluate
the presence of liver steatosis. When steatosis
is identified, they suggest using non-invasive
serum biomarkers to look for liver fibrosis.
Patients at low risk for advanced fibrosis are
followed-up every 2 years by repeating liver
enzymes and fibrosis scores, whereas those at
intermediate or high risk need to be referred
to specialists to exclude other chronic liver
diseases, to better assess disease severity and
possibly to initiate specific therapy [5].
Definition of risk for NASH:
Risk for NASH was defined as those
who presented at least one of the following
biochemical and metabolic parameters:
fasting glucose ≥100 mg/dL, TG ≥150 mg/dL,
AST >54 IU/L and ALT >42 IU/L [6].
All patients were subjected to:
Full history taking with special attention to
: Presence of any symptoms that may
accompany with fatty liver disease (e.g.:
fatigue and right hypochondrial pain).
Presence of dyslipidemia signs (elevated
serum cholesterol and TG levels). Presence of
diabetes.
Diabetes mellitus was diagnosed when fasting
glucose was ≥126 mg/dl or the patient was
treated with anti-diabetic drugs, or had
impaired fasting glucose (IFG)–when the
fasting glucose level ranged between 100 and
125 mg/dL [7]. History of alcohol intake.
Symptoms suggesting liver cirrhosis and/or
liver cell failure (e.g.: history of jaundice,
ascites, hepatic encephalopathy…..etc.).
Clinical examination: General examination
with attention to BMI: Height and weight
were measured while the patients had light
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clothes and no shoes, and the BMI measured
was according to the equation:
BMI = Weight (kg)/ Height2 (m).
Obesity was diagnosed when BMI was
≥30 kg/m2, and overweight when BMI was
≥25 and <30 kg/m2. [7].
Local abdominal examination with especial
attention to: Presence of hepatomegaly or
splenomegaly. Any stigmata of liver cirrhosis
and/or liver cell failure (e.g.: jaundice, ascites,
spider nevi ….etc.).
Laboratory investigations including: Liver
profile [Serum levels of Aspartate transferase
enzyme (AST), Alanine transferase enzyme
(ALT) Albumin, Gamma glutamyl transferase
(γGT)]. Coagulation profile Prothrombin time
(PT) and (INR), to exclude liver cell failure
(LCF). Fasting blood sugar (FBS). Complete
blood count (CBC). Fasting blood sugar
(FBS). Lipid profile including: Triglyceride,
total cholesterol & low- density lipoprotein
(LDL), high density lipoprotein (HDL).
Serological markers to exclude other causes
of chronic liver diseases, autoimmune
hepatitis and metabolic liver disease. Viral
markers (HBs Ag, HBc IgG, HCV Ab).
Autoantibodies (Anti smooth muscle antibody
(ANA) and Anti mitochondrial antibody
(ASMA). Serum Ferritin.
Abdominal
ultrasonography:
The
equipment used was Medisone Sonoace 9900
Duplex ultrasonography equipment with a
curved convex 3.5-5 MHz transducer that has
a real time B mode imaging system with
pulsed wave and Color Doppler facilities was
used. For presence of ultra-sonographic
features of fatty liver, which include increased
echogenicity of liver by ultrasound
examination which is the characteristic
ultrasonographic finding that identified
hepatic steatosis. The increased echogenicity
compared to the spleen and kidney. A loss
definition of de_nition of the hemi-diaphragm
and decreased detail of the intrahepatic
architecture (particularly the portal veins and
the hepatic vein trunk) are supportive findings
[8].
Fibroscan technique:
Transient
elastography
(TE)
(FibroScan; Philips IU22) is a new tool,
designed for the non- invasive study of liver
Farag A., et al
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stiffness. TE uses an ultrasound transducer
probe, mounted on the axis of a vibrator.
Fibroscan (EchoSens) examination was
done as follows:
Patients lied in the dorsal decubitus
position with their right arm in maximal
abduction. The tip of the probe transducer
was covered with coupling gel. The tip of the
probe transducer was placed on the skin
between the ribs at the level of the right lobe
of the liver. A vibration of mild amplitude and
low frequency was transmitted from the
vibrator to the tissue by the transducer itself.
A pulse-echo acquisition was performed at
this time to follow the propagation of the
shear wave and measure its velocity, which
was directly related to the liver stiffness, the
harder the tissue, the faster the propagation of
the shear wave [9].
Liver stiffness measurement was
expressed in kilopascals (KPa). Ten
successful acquisitions were performed on
each patient. The median value was expressed
as final result of the liver stiffness. The
success rate is calculated as the ratio of the
number of successful acquisitions to that of
the total number of acquisitions and a success
rate of at least 60% or the interquartile range
(IQR) <30% were considered reliable.
New model score including the following
clinical and laboratory parameters [body mass
index (BMI), US of liver, Liver stiffness,
LDL, HDL, TG, ALT, AST, AST/ALT ratio,
Platelet, mean platelet volume (MPV),
Ferritin and Fasting Blood Glucose]. the new
scoring system for steatosis, where NAFLD
score was calculated as per the following
formula: - 1.675+0.037 X age (years) + 0.094
X body mass index (BMI, kg/m2) + 1.13 X
impaired fasting glucose/diabetes (yes = 1, no
= 0) + 0.99 X AST/ALT ratio - 0.013 X
platelet (X109 /L) - 0.66 X Albumin (g/dL)
(table 1).
The basis of creation of the new score
BMI: Obesity is associated with a spectrum
of liver abnormalities, known as nonalcoholic
fatty liver disease (NAFLD), characterized by
an increase in intrahepatic triglyceride
(IHTG) content (i.e. steatosis) with or without
inflammation and fibrosis (i.e. steatohepatitis)
[10]
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US of liver : Ultrasound is a non-invasive,
widely available, and accurate tool in the
detection of Non-alcoholic fatty liver disease
(NAFLD) [11].
Liver stiffness: considered to be one of the
direct consequences of the fibrotic evolution
of chronic liver disease and function of the
extent of hepatic fibrosis. [12]
Biochemical markers and lipid profile
(LDL, HDL, TG, ALT, AST, AST/ALT ratio)
are associated with NAFLD. Thus, it is
indicated that in patients with NAFLD, there
are considerable changes in biochemical
markers. Thus, it seems essential that in
clinical settings in cases in which biochemical
and lipid changes are observed, sonography
should be performed to examine individuals
with NAFLD, since early diagnosis prevents
further complications and delays them. [13].
Mean platelet volume: Patients with NAFLD
have significantly higher values of MPV
when compared to the healthy controls, and
values of MPV could be used for prediction
of the degree of liver steatosis and fibrosis in
NAFLD patients and may be beneficial
considering that they are simple, easy to
measure, and cost-effective and are routinely
checked in everyday practice [14].
Serum Ferritin: the level of Serum ferritin
(SFL) can be an irrespective indicator to
assess the progression of hepatic fibrosis in
the patients with NAFLD because of its
association with hepatic iron storage and
hepatic inflammation. [15]
Fasting Blood Glucose : there is an
independent nonlinear association between
FBG and NAFLD, and the increase in FBG
may indicate an increased risk of NAFLD.
[16]
GULAB score: consists of five clinical and
laboratory parameters: gender; US findings;
fasting lipid levels; ALT levels; and BMI.
The minimum and maximum scores were 1
and 7, respectively [17].
BARD
score
calculator
(http://www.pmidcalc.org).
The BARD score was composed of 3
variables: AST/ALT ratio ≥0.8– 2 points; a
BMI ≥28–1 point; and the presence of
diabetes – 1 point. The possible score ranges
from 0 to 4 points. According to the results of
Farag A., et al
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Harrison et al. [18] BARD scores equaling 0
or 1 are of high (96%) negative predictive
value (NPV) for advanced fibrosis.
Scoring of fibrosis:
APRI was defined: [100 x (AST/upper limit
of normality)/platelet count (109/L) [19].
FIB-4 values were calculated automatically
using the formula age (years) × AST
[U/l]/(platelets [109/L] ×(ALT [U/l])1/2, in
which the age of the patient was the age at the
time of the liver biopsy[20].
Statistical Analysis
Data were collected, tabulated and analyzed
by SPSS 20 software [21]. According to the
type of data, qualitative data was represented
as number and percentage, quantitative
continues group represent by mean ± SD. The
following tests were used to test differences
for significance; difference and association of
qualitative variables by Chi square test (X2).
Differences between quantitative independent
groups by t test. The Mann-Whitney U and
Kruskal Wallis tests were used to compare
non-normal distribution data between two or
multiple groups, respectively. Univariate
logistic regression analysis was carried out on
variables of patients with or without NAFLD.
A correlation analysis was done and Receiver
operating characteristic (ROC) curve analysis
was used to identify optimal cut-off values.
Area Under Curve (AUC) was also
calculated. Variables significantly associated
with the presence of NAFLD in univariate
analysis (P < 0.05) were then subjected to
multivariate logistic analysis to identify
factors independently associated with
NAFLD
RESULTS
Table (2), showed that there was a high
statistically significant difference among both
studied groups as regard age, weight, height
and BMI. All non-NASH group were not
diabetic versus 50% of NASH group and
16.7% of them were diabetic, with a high
statistically significant difference among both
of them. There was a high statistically
significant difference among both studied
groups as regard MPV and fasting blood
sugar, which was higher among NASH risky
group, while there was no significant
difference as regard WBCs, RBCs, platelet
541 | P a g e
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count and hemoglobin. There was a high
statistical significant difference among both
studied groups as regard liver function tests,
lipid profile and ferritin. There was a high
statistical significant difference among both
studied groups as regard APRI and FIB-4,
which was all higher among cases with
NASH.
Table (3), showed that there was a high
statistically significant difference among both
studied groups as regard LMS and severity of
fibrosis, which was all higher among cases
with NASH. Table (4), showed that in NASH
cases there was a statistically significant
positive correlation between the new studied
score and BARD score, also there was a
positive correlation with BMI, Hb, FBS,
RBCs, platelet count, MPV, HDL, TG,
albumin, ferritin, NAFLD and GULAP score
but not reach significant level. While there
was a negative correlation with age, WBCs,
LDL, total cholesterol, ALT, AST, GGT,
FIB4 and APRI, but not reach significant

Doi: 10.21608/zumj.2020.33313.1883

level. In non-NASH cases there was a
positive correlation between the new studied
score with BMI, Hb, WBCs, RBCs, TG, ALT,
AST, GGT and GULAP score, but not reach
significant level. While there was a negative
correlation with age, FBS, Platelet count,
MPV, LDL, HDL, total cholesterol, albumin,
LSM, FIB4, APRI, BARD and NAFLD score
but not reach significant level. Table (5),
showed that after applying Multivariate
analysis of signify cant variables for the new
studied score among studied NASH group, it
was proven to be non-significant predictor.
Table (6) and Fig. (2), showed that the
sensitivity of new score in detection of NASH
was 97.9% versus 91.7%, 89.6% and 100% of
NAFLD, BARD and GULAB scores,
respectively, with ability of 59.4% to exclude
truly negative cases versus 68.8%, 93.8% and
96.9% of NAFLD, BARD and GULAB
scores, respectively. The accuracy of new
score was the same as NAFLD score 82.5%
versus 91.3% of BARD score.

Table (1): Suggested new scoring system for steatosis
0
1
2
BMI (kg/m2)
<25
25-29.9
≥30
US (of liver)
No steatosis
Focal steatosis
Diffuse steatosis
Liver Stiffness
<6 kPa (F0)
6-8.8 kPa (F1-2)
≥8.9 kPa (F3-4)
LDL
≤130 (mg/dL)
>130 (mg/dL)
N/A
HDL
≥40 (mg/dL)
<40 (mg/dL)
N/A
TG
≤150 (mg/dL)
>150 (mg/dL)
N/A
ALT
Normal
Raised
N/A
AST
Normal
Raised
N/A
AST/ALT ratio
<1
>1
N/A
3
3
Platelet
>200 (×10 /cc)
≤200 (×10 /cc)
N/A
MPV
Normal
Raised
N/A
Ferritin
Normal
Raised >1.5 upper limit
N/A
FBS
≤110 (mg/dL)
111-125.9 (mg/dL)
≥126 (mg/dL)
N/A : not applicable
BMI; body mass index, US; ultrasonography, LDL; low-density lipoprotein, HDL; high-density
lipoprotein, TG; triglyceride, ALT; Alanine aminotransferase, AST; aspartate aminotransferase,
MPV; mean platelet volume, FBS; fasting blood sugar.
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Table (2): Baseline characteristics of enrolled participants:
NASH group
Non-NASH group
p value
N=48
N=32
Age (year)
55.1 ± 9.3
35.2 ± 5.2
<0.001
Gender
Male N (%)
23 (46.9%)
97 (78.9%)
<0.001
Female N (%)
26 (53.1%)
26 (21.1%)
Weight (Kg)
89.4± 12.2
73.1 ± 10.3
<0.001
Height (Meter)
1.62 ± 0.1
1.71 ± 0.1
<0.001
BMI
33.9 ± 5.3
24.2 ± 2.3
<0.001
Diabetes
Non-diabetic N (%)
24 (50%)
32 (100%)
Diabetic N (%)
8 (16.7%)
0
<0.001
Pre-diabetic N (%)
16 (33.3%)
0
WBC’s (×103 cells/cc)
6.8 ± 1.56
6.9 ± 1.57
0.55
Hb (g/dl)
12.2 ± 0.82
12.6 ± 0.85
0.06
3
Platelet (×10 /cc)
262.4 ± 69.9
267.3 ± 68.8
0.758
RBCs
4.2 ± 0.32
4.3 ± 0.31
0.112
MPV
13.8 ± 1.89
10.5 ± 1.27
<0.001
FBS (mg/dl)
105.7 ± 16.88
77.7 ± 6.18
<0.001
ALT(IU/L)
43.6 ± 6.8
19.9 ± 3.64
<0.001
AST(IU/L)
42.9 ± 6.8
18.9 ± 3.3
<0.001
Albumin (g/dl)
3.2 ± 0.12
3.5 ± 0.1
<0.001
GGT (U/L)
35.7 ± 5.7
19.9 ± 3.4
<0.001
TC (mg\dl)
174.7 ± 13.5
147.8 ± 15.7
<0.001
TG (mg\dl)
188.9 ± 23.3
87.4 ± 19.8
<0.005
LDL (mg\dl)
92.1 ± 15.1
70.9 ± 16.2
<0.001
HDL (mg\dl)
44.8 ± 5.6
59.4 ± 3.02
<0.001
Ferritin (g/dl)
189.02 ± 35.3
69.5 ± 19.1
<0.001
APRI score
0.43 ± 0.13
0.19 ± 0.05
<0.001
FIB-4 score
1.44 ± 0.47
0.59 ± 0.17
<0.001
BMI; body mass index, WBC’s; white blood cells, Hb; hemoglobin, RBCs; red blood cells, MPV;
mean platelet volume, FBS; fasting blood sugar, ALT; Alanine aminotransferase, AST; aspartate
aminotransferase, GGT; gamma-glutamyl transferase, TC; total cholesterol, TG; triglyceride, LDL;
low-density lipoprotein, HDL; high-density lipoprotein, APRI; AST to Platelet Ratio Index, FIB-4;
fibrosis-4.
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Table (3): Difference among both studied groups as regards LSM, stage and severity of
fibrosis.

LSM
Stage of fibrosis N (%)
1
2
Correlated fibrosis severity N (%)
F0-F2
F3-F4
Indeterminate
DFL N (%)
Yes
No
FFL N (%)
Yes
No

NASH group
N=48

Non-NASH group
N=32

p value

6.4 ± 1.59

5.7 ± 1.53

0.03

38 (79.2%)
10 (20.8%)

27 (84.4%)
5 (15.6%)

0.559

11 (22.9%)
9 (18.8%)
28 (58.3%)

32 (100%)
0
0

38 (79.2%)
10 (20.8%)

13 (40.6%)
19 (59.4%)

0.001

10 (20.8%)
38 (79.2%)

19 (59.4%)
13 (40.6%)

0.001

<0.001

LSM; liver stiffness measurement, DFL; diffuse fatty liver, FFL; focal fatty liver.
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Table (4): Pearson’s correlation between new studied score and other clinical data among
studied groups :
New score (NASH cases)
New score (non -NASH cases)
Variables
r
P-value
r
P-value
-0.267
0.067 NS
-0.031
0.867 NS
Age
0.192
0.921 NS
0.184
0.321 NS
BMI
0.158
0.299 NS
0.138
0.499 NS
Hb
-0.180
0.232 NS
0.173
0.332 NS
WBCs
0.077
0.856
NS
0.247
0.156 NS
RBCs
0.242
0.098 NS
-0.185
0.398 NS
FBS
0.022
0.882 NS
-0.02
0.982 NS
Platelet count
0.003
0.980 NS
-0.195
0.280 NS
MPV
-0.191
0.194 NS
-0.171
0.394 NS
LDL
0.101
0.494 NS
-0.025
0.944 NS
HDL
0.202
0.169 NS
0.283
0.116 NS
Triglycerides
-0.103
0.454 NS
-0.110
0.554 NS
Total cholesterol
-0.075
0.615 NS
0.178
0.315 NS
ALT
-0.056
0.703 NS
0.116
0.532 NS
AST
0.045
0.763 NS
-0.05
0.763 NS
Albumin
0.071
0.631 NS
0.00
1.0
NS
Ferritin
-0.064
0.663 NS
0.164
0.363 NS
GGT
0.094
0.523 NS
-0.224
0.243 NS
LSM
-0.139
0.346 NS
-0.101
0.581 NS
FIB4
-0.017
0.910 NS
-0.109
0.551 NS
APRI
-0.049
0.791 NS
BARD
0.300
0.038
S
0.046
0.757 NS
-0.005
0.997 NS
NAFLD score
0.05
0.735 NS
0.115
0.135 NS
GULAP score
NS: P-value >0.05 (not significant), S: P-value<0.05 (significant).
BMI: body mass index; Hb: Hemoglobin; WBCs: White blood cells; RBCs :Red blood cells; FBS:
fasting blood sugar; MPV: mean platelet volume; LDL: low-density lipoproteins; HDL: Highdensity lipoproteins; ALT: Alanine transferase enzyme; AST: Aspartame transaminase; GGT:
Gamma-glutamyl transferase; LSM: Liver stiffness measurement; FIB4: Fibrosis-4; APRI : AST to
Platelet Ratio Index; BARD: BMI, AST/ALT ratio, and diabetes; NAFLD: Non-alcoholic fatty
liver disease; GULAB: scoring system for predicting NASH.
Table (5):
Multivariate regression analysis of significant predictors for new studied score
among the studied NASH group.
Regression coefficient
SE
P-Value
BARD score

0.170

0.103

0.104 NS

r=0.896 , r2 =0.803
ANOVA P<0.000*
Durbin-Waston ratio=1.768
BARD score: BMI, AST/ALT ratio, and diabetes, SE= standard error
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Table (6):

Reliability data of standard and new scores as a predictor for NASH.
Cut
Variables
AUC P-value PVP PVN sensitivity specificity accuracy
off
BARD

2.5 0.925 <0.001 95.6% 85.7%

89.6%

93.8%

91.3%

NAFLD score
GULAB score
New score

-2.35 0.921 <0.001 81.5% 84.6%
3.5 0.996 <0.001 98% 100%
1.5 0.789 <0.001 78.3
95

91.7%
100%
97.9

68.8%
96.9%
59.4

82.5%
98.8%
82.5

BARD: BMI, AST/ALT ratio, and diabetes, NAFLD: Non-Alcoholic Fatty Liver Disease, GULAB
scoring system for predicting NASH based on five clinical and laboratory parameters: (Gender:
male = 1, female = 0; Ultrasound abdomen: DFL = 2, FFL = 1; Lipid (fasting) levels: raised serum
cholesterol or serum triglyceride or serum LDL = 1, normal lipid levels =0; ALT: raised =1, normal
= 0; BMI: >27=1,<27=0).
Enrollment

84 patients suffering from dyspeptic symptoms,
fatigue and unexplained elevation of
aminotransferases
Excluded (n = 4) not
meeting inclusion
criteria
Randomized (n = 80)

Allocation
Group I: with risk of NASH (n =
48)

Group II : without risk of
NASH (n = 32)

Follow up
Loss of follow up (n=2)

Loss of follow up (n=2)

Analysis
46 patients were analyzed and
30 patients were analyzed and
completed the study
completed the study
Fig. (1) : Flow chart of patients in the studied groups
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Fig. (2): Receiver operating characteristics (ROC) curve for standard and new scores as
predictors of NASH
DISCUSSION
NAFLD/NASH
are
currently
emerging as the primary causes of chronic
liver disease, namely cirrhosis, and
hepatocellular carcinoma worldwide. While in
the era in which effective hepatitis C therapy
is a reality and alcohol abuse is being curbed
in some populations, the increased prevalence
of
obesity,
type
2
diabetes
and
NAFLD/NASH affect both the developed and
developing countries [4].
Conventionally, NASH diagnostics relies on a
liver biopsy (LB) when all other causes of
liver damage have been discarded in which
hepatocyte ballooning, inflammation, and
fibrosis are demonstrated. Alternatively, noninvasive strategies include liver stiffness
measurement
(LSM)
using
transient
elastography (TE) [22].
This cross-sectional study was carried
on (80) Egyptian patients presenting to the
hepatology outpatient clinic, Zagazig
University Hospitals suffering from dyspeptic
symptoms, fatigue and unexplained elevation
Farag A., et al
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of aminotransferases and having fatty liver by
ultrasound.
In the present study, NASH was recorded in
48 (60%) of patients while 32 (40%) of
patients had steatosis without proof of
steatohepatitis. This came in agreement with
Tasneem et al. [17] who reported that NASH
was found in 78 (81.3%) patients while the
remaining 18 (18.7%) patients had steatosis
without evidence of steatohepatitis.
In the present study, the mean age of
the patients in the study was 55.1 ± 9.3 years
old in NASH group while it was 35.2 ± 5.2 in
No NASH group with the statistically
significant difference in both groups as regard
the age. This result was in accordance with
the result in the study of Sepulveda-Villegas
et al. [4] who found that the patients in
NASH group were older than those in the
non-risk group (39.5 ± 13 vs. 33.9 ± 13.5
years, p = 0.0021). This may indicate the
direct relation between old age and high
incidence of NASH.
In the current study, the male
distribution was predominant in the current
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study (65%) with a significant difference
between both groups. This was consistent
with Angulo et al. [23], where the male
distribution was 53%, denoting the
relationship between male gender and
metabolic syndrome.
In the present study, the BMI was 33.9
± 5.3 (kg/m2) in NASH group while BMI in
No NASH group was 24.2 ± 2.3 (kg/m2) with
the statistically significant difference among
both groups. This result was in agreement
with the result in the study of SepulvedaVillegas et al. [4] who found that the patients
in NASH group were obese (average BMI
32.7 ± 9.3 versus 25.2 ± 6.2 kg/m2, p =
0.0012), and in disagreement with our study,
the study of Beymer et al. [24] showed no
difference regarding BMI between both
groups with and without NASH. This
difference may be due to different inclusion
and exclusion criteria in their study and ours.
In the current study, the co-morbid
conditions including obesity, DM and
dyslipidemia were highly significant in the
NASH group. All cases in No NASH group
were non-diabetic while 33.3% and 16.7%
were pre-diabetic and diabetic respectively.
Such risk factors were significantly related to
NASH development. This was in agreement
with the study by Hashemi et al. [25], which
revealed a significant increase in the rate of
DM and BMI as steatosis being advanced.
Also, Park et al. [26] found that
patients with NASH had a highly significant
incidence of diabetes and obesity comparing to
non-NASH patients
In this work, we assessed the relation
between several laboratory markers and the
risk of NASH, and we found that elevated
blood sugar, high lipid profile and elevated
liver enzymes (denoting ongoing necroinflammation) are all considered risk factors
of developing NASH.
In agreement with our study,
Sepulveda-Villegas et al. [4] who found that
regarding ALT, AST, TG, TC, HDL, LDL
and glucose there was a statistically
significant difference between both studied
groups (with and without NASH).
In the present study, there was no
significant difference regarding platelet count
Farag A., et al
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in both groups. This came in agreement with
Park et al. [26] who found no significant
difference regarding platelet count (p = 0.48).
In the current study, there was a high
statistically significant difference among both
studied groups as regard ferritin with
increased its level in the NASH group. This
came in agreement with Kowdley et al. [27]
who found that increased risk of NASH was
associated with higher serum ferritin values.
In the present study, there was a
highly significant difference between both
studied groups as regard GGT. This came in
agreement with Sakugawa et al. [28] who
found a significant difference between GGT
level and liver fibrosis severity.
In the current study, diffuse fatty liver
was more evident in the NASH group
(79.2%) than in the No NASH (40.6%).
While focal fatty liver changes were
significantly more common features among
the No NASH group (59.4%) than in the
NASH group (20.8%). This came in
agreement with Pulzi et al. [29] who found
that presenting normal (or non-steatosis) more
frequently in Non-NASH (26/49) than in
NASH (3/13) (p = 0.048). Abdominal US
presented sensitivity and specificity of 76.9%
and 46.9%, respectively, to identify NASH.
In this study, we proposed a diagnostic
model using clinical, laboratory and imaging
data to improve the differential diagnosis of
patients who have NASH from those who
don’t have it. Patients with a score of more
than 1.5 are more likely to have NASH
(sensitivity 97.9%, specificity 59.4%, NPV
95%, PPV 78.3%). This composite index
seems to be a good discriminator to identify
NASH patients with more severe disease.
In the present study in comparison
between the new score and other scores,
sensitivity of new score in detection of NASH
was 97.9% versus 91.7%, 89.6% and 100% of
NAFLD, BARD and GULAB scores
respectively, with ability of 59.4% to exclude
truly negative cases versus 68.8%, 93.8% and
96.9% of NAFLD, BARD and GULAB
scores respectively. The accuracy of the new
score was the same as NAFLD score 82.5%
versus 91.3% and 98.8% of BARD and
GULAB scores respectively
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As can be seen here, the sensitivity,
specificity, PPV and NPV obtained by the
measurements we proposed in this study are
to some extent similar to the ones previously
reported [30].
Despite the low specificity (we added
it to the limitations of the study), the new
score revealed a high sensitivity compared to
the previously known scores that can be used
as a good negative test to exclude NASH in
the screening of high risk patients
Conclusion: The new model score considered
simple, non-invasive and low-cost tool and
can be used as a good negative test to exclude
NASH in the screening of high risk patients
and markedly reduce the need for liver
biopsies in NAFLD patients.
Limitations : All auxiliary biomarker/scores
for NAFLD/NASH diagnosis have pros and
cons, and some do not consider the full
spectrum of metabolic risk factors related to
NASH. The limitation of imaging is that it
cannot differentiate bland steatosis from
steatohepatitis which is possible only with
liver biopsy.
Recommendation : Wide-scale studies are
recommended to evaluate the role of the new
score model compared to liver biopsy in
assessing the risk of NASH. Periodic
monitoring of old patients with risk of NASH
could aid to improve the quality of life and
prevent the appearance of co-morbidities in
the next decades of life.
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